Product Description
Misoprostol is a synthetic prostaglandin E1 analogue that is used off-label for a variety of indications in the practice of obstetrics and gynecology, including medication abortion, medical management of miscarriage, induction of labor, cervical ripening before surgical procedures, and the treatment of postpartum hemorrhage. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760893/)
Mechanisms of Action: EP2 Agonist,EP4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Sublingual,Vaginal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Duodenal Ulcer | Arthritis, Rheumatoid | Arthritis | Osteoarthritis
Known Adverse Events: Abdominal Pain | Dizziness | Headache | Pain Unspecified | Gastritis | Constipation | Diarrhea | Dyspepsia | Flatulence
Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Pakistan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Non-alcoholic Steatohepatitis
Phase 1: Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05342974 | P1 |
Active, not recruiting |
Pregnancy Outcomes |
2023-12-31 |
|
| 3280221MSGE | P2 |
Completed |
Non-alcoholic Steatohepatitis |
2022-12-31 |
|
| DV-MV-MO | P3 |
Active, not recruiting |
Unknown |
2017-07-17 |